High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate whether high-dose icotinib treatment beyond
disease progression is beneficial for NSCLC patients who have EGFR mutation and who have
responded to EGFR TKI.